drugset
drugset / Trial / NCT07205900

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900 ↗

Phase 2 Active not recruiting 267 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupTriple-blindTreatment

Summary

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

Timeline

Start
2025-12-02
Primary completion
2027-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HM15275 Unknown — Subcutaneous

Indications

obesity disorder